The first chikungunya vaccine may be on its way with phase 3 trials of a single-shot jab developed by French biotech company Valneva showing the vaccine to be generally safe, well tolerated and provoking an immune response. The study was conducted in the US. Its success will have significant implications for nations like India where chikungunya is endemic.
from Times of India https://ift.tt/5B3a41k
from Times of India https://ift.tt/5B3a41k